SCHEDULE: Commodore Capital Discloses 9.9% Stake in Palisade Bio

Commodore Capital LP and its affiliates have reported a 9.9% passive ownership stake in Palisade Bio, Inc., totaling 9,690,665 shares.

Summary

• Commodore Capital LP, Commodore Capital Master LP, Robert Egen Atkinson, and Michael Kramarz collectively reported beneficial ownership of 9,690,665 shares of Palisade Bio, Inc. common stock.
• This represents a 9.9% stake in the company's common stock.
• The ownership includes 9,332,443 shares of common stock and 358,222 shares underlying a pre-funded warrant.
• An additional 4,827,492 shares underlying a pre-funded warrant are excluded from this calculation due to a 9.99% beneficial ownership limitation.
• The ownership percentage is based on 96,645,431 shares outstanding as of October 1, 2025, as reported in the Issuer's Rule 424(b)(4) Prospectus, plus the 358,222 exercisable shares.
• The filers certified that the securities were acquired and are held for passive investment purposes, not to change or influence control of the issuer.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership and does not contain information that inherently indicates a positive or negative sentiment regarding the company's performance or prospects.

Positives

• A significant institutional investor, Commodore Capital, has disclosed a 9.9% passive stake in Palisade Bio, Inc., potentially signaling confidence in the company's long-term prospects.

Negatives

• No specific negative information is disclosed in this Schedule 13G filing, which is a routine ownership disclosure.

Risks

• No specific risks related to Palisade Bio, Inc.'s operations or financial health are detailed in this beneficial ownership disclosure.

Future Outlook

This filing does not provide any forward-looking statements or guidance regarding Palisade Bio, Inc.'s future performance or strategic direction.

Management Comments

• The reporting persons, including Michael Kramarz and Robert Egen Atkinson, certified that the securities were not acquired or held for the purpose of changing or influencing the control of Palisade Bio, Inc., but rather for passive investment.

Industry Context

The disclosure of a significant institutional stake in a biotechnology company like Palisade Bio, Inc. is a common event in the sector, often reflecting investor interest in specific therapeutic pipelines or market opportunities. Such filings provide transparency regarding major ownership positions.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor holding a 9.9% stake may influence market perception and trading activity, potentially increasing investor confidence.

Next Steps

• No specific future actions, events, or milestones are mentioned in this beneficial ownership disclosure.

Key Dates

Keywords

Palisade Bio, Commodore Capital, Beneficial Ownership, Institutional Investor, Common Stock, Biotechnology, Passive Investment, SEC Filing, Schedule 13G